Pak Fah Yeow International Limited (HK:0239)
:0239
Want to see HK:0239 full AI Analyst Report?
Top Page
Pak Fah Yeow International Limited
(0239)
Select Model
Select Model
Rating:86Outperform
Price Target:
HK$3.00
▲(26.05% Upside)
Action:Reiterated
Date:05/04/26
The score is driven primarily by strong financial performance (high profitability, very low leverage, and strong recent cash generation) and very attractive valuation (low P/E and high dividend yield). Technicals are supportive with price above key moving averages, but momentum looks somewhat stretched (high Stoch and RSI near 65), tempering the overall score.
Positive Factors
Conservative balance sheet
Extremely low leverage and a conservative balance sheet provide durable financial flexibility: easier access to credit, resilience in downturns, and capacity to fund dividends or opportunistic acquisitions without stressing cash flow. This lowers long-term solvency risk and supports capital allocation optionality.
Negative Factors
Top-line volatility
Repeated revenue declines across recent years demonstrate top-line instability, which can make earnings and cash forecasts less reliable. For a landlord-centric model, fluctuating rental income or timing of property disposals can materially swing operating results and impair predictability of returns over a multi-quarter horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage and a conservative balance sheet provide durable financial flexibility: easier access to credit, resilience in downturns, and capacity to fund dividends or opportunistic acquisitions without stressing cash flow. This lowers long-term solvency risk and supports capital allocation optionality.
Read all positive factors
Pak Fah Yeow International Limited (0239) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$772.87M
Dividend Yield7.52%
Average Volume (3M)22.62K
Price to Earnings (P/E)3.6
Beta (1Y)-0.15
Revenue Growth-9.66%
EPS Growth16.17%
CountryHK
Employees106
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.30
Shares Outstanding311,640,000
10 Day Avg. Volume26,750
30 Day Avg. Volume22,616
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)1.02
Price to Sales (P/S)3.45
P/FCF Ratio6.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pak Fah Yeow International Limited Business Overview & Revenue Model
Company Description
Pak Fah Yeow International Limited, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the Uni...
How the Company Makes Money
The company makes money mainly through income and returns generated from its investment property portfolio. Key revenue and earnings drivers typically include: (1) rental income earned from leasing its investment properties to tenants under lease ...
Pak Fah Yeow International Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
83
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 213.88M | 236.91M | 259.31M | 147.20M | 139.82M |
| Gross Profit | 133.14M | 203.20M | 167.59M | 74.06M | 68.71M |
| EBITDA | 115.35M | 105.73M | 136.81M | 45.90M | 54.67M |
| Net Income | 91.35M | 78.63M | 105.04M | 29.95M | 38.19M |
Balance Sheet | |||||
| Total Assets | 828.37M | 843.35M | 907.47M | 823.14M | 837.75M |
| Cash, Cash Equivalents and Short-Term Investments | 344.54M | 290.02M | 277.61M | 180.34M | 178.28M |
| Total Debt | 6.87M | 4.20M | 4.74M | 5.50M | 16.21M |
| Total Liabilities | 105.63M | 111.45M | 142.28M | 115.91M | 130.03M |
| Stockholders Equity | 722.75M | 731.91M | 765.18M | 707.23M | 707.72M |
Cash Flow | |||||
| Free Cash Flow | 112.33M | 78.02M | 144.84M | 39.76M | 69.54M |
| Operating Cash Flow | 112.77M | 78.96M | 147.90M | 39.92M | 70.36M |
| Investing Cash Flow | -63.29M | -3.19M | 16.65M | -6.67M | -565.00K |
| Financing Cash Flow | -57.67M | -67.54M | -48.96M | -33.91M | -22.41M |
Pak Fah Yeow International Limited Technical Analysis
Positive
2.38
Price Trends
2.42
Positive
2.41
Positive
2.41
Positive
Market Momentum
<0.01
Positive
55.09
Neutral
76.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0239, the sentiment is Positive. The current price of 2.38 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.42, and below the 200-day MA of 2.41, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.09 is Neutral, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0239.
Pak Fah Yeow International Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | HK$772.87M | 3.58 | 12.80% | 7.52% | -9.66% | 16.17% | |
82 Outperform | HK$1.35B | 5.52 | 10.88% | ― | 2.39% | 7.94% | |
57 Neutral | HK$669.13M | 25.15 | 1.57% | 9.43% | -21.54% | -81.79% | |
52 Neutral | HK$823.45M | -45.08 | -3.39% | ― | -15.98% | 93.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$356.60M | 43.65 | -1.17% | 7.50% | 59.60% | -351.02% | |
45 Neutral | HK$160.48M | -4.22 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:0239
Pak Fah Yeow International Limited
2.48
0.23
10.22%
HK:8049
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
2.41
0.46
23.40%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.32
-0.04
-11.11%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.21
-41.18%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.12
0.82
273.33%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.79
-0.06
-7.06%
Pak Fah Yeow International Limited Corporate Events
Pak Fah Yeow Sets 2026 AGM to Approve Dividends, Director Mandates and Share Buyback
Apr 29, 2026
Pak Fah Yeow International Limited has convened its annual general meeting for 2 June 2026 in Hong Kong to present the 2025 financial statements and seek shareholder approval for key corporate matters. The board proposes a final dividend of HK3.8 ...
Pak Fah Yeow Moves to Modernise Bye-Laws With Treasury Shares and Hybrid Meetings
Mar 30, 2026
Pak Fah Yeow International Limited plans to amend its bye-laws to modernise its corporate governance framework and enhance operational flexibility. The proposed changes, which require shareholder approval at the upcoming annual general meeting, in...
Pak Fah Yeow Profit Rises on Lower Fair Value Losses Despite Weaker Healthcare Revenue
Mar 30, 2026
Pak Fah Yeow International reported a 9.7% decline in revenue and a 7.8% drop in underlying recurring profit for 2025, largely due to weaker sales in its healthcare segment, while shareholders’ funds and net asset value per share edged down ...
Pak Fah Yeow proposes final and special dividends, sets key shareholder dates
Mar 30, 2026
Pak Fah Yeow International Limited has recommended a final dividend of HK3.8 cents per share and a special final dividend of HK7.2 cents per share for the year ended 31 December 2025, payable to shareholders whose names appear on the company’...
Pak Fah Yeow Declares Final Dividend for 2025 Financial Year
Mar 30, 2026
Pak Fah Yeow International Limited has declared a final ordinary dividend of HKD 0.038 per share for the financial year ended 31 December 2025, underscoring its continued commitment to returning cash to shareholders. The dividend, subject to share...
Pak Fah Yeow Declares Special Final Dividend for 2025
Mar 30, 2026
Pak Fah Yeow International Limited has declared a special final dividend of HKD 0.072 per share for the financial year ended 31 December 2025, payable in Hong Kong dollars subject to shareholder approval on 2 June 2026. The dividend will go ex-div...
Pak Fah Yeow Sets March 2026 Board Meeting to Approve 2025 Results and Dividend
Mar 18, 2026
Pak Fah Yeow International Limited has scheduled a board meeting for 30 March 2026 to review and approve the annual results for the year ended 31 December 2025, and to consider a possible final dividend. The outcome of this meeting will determine ...
Pak Fah Yeow Flags Higher 2025 Profit on Smaller Property Valuation Losses
Mar 13, 2026
Pak Fah Yeow International Limited has alerted investors that it expects consolidated net profit attributable to shareholders to rise to about HK$91.3 million for the year ended 31 December 2025, up from HK$78.6 million a year earlier. The improve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.